ArticleFrontiers in pediatrics2025
Management of pediatric portal vein cavernous transformation: a seven-case single-center study.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pancytopenia With Hypocellular Bone Marrow Revealing Extrahepatic Portal Venous Obstruction and Cavernous Transformation in a Child: A Case Report of a Diagnostic Challenge.Clinical case reports · 2026Article
- Endoscopic Hemostasis as a Bridge to Surgical Portal Decompression in Children with Portal Hypertensive Bleeding: A Staged Endoscopic-Surgical Strategy.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cavernous transformation of the portal vein (CTPV) is one of the significant pathogenic factors of prehepatic portal hypertension in children. The Rex shunt, by reconstructing an intrahepatic portal venous pathway, not only effectively reduces portal pressure and restores physiological hepatic blood flow, but also promotes normal growth and development, making it the treatment of choice for CTPV. In contrast, traditional non-selective shunting procedures primarily alleviate symptoms of portal hypertension without restoring hepatic perfusion, thereby compromising growth potential. For patients unsuitable for the Rex shunt, living donor liver transplantation provides a definitive cure. Overall, both the Rex shunt and liver transplantation improve long-term outcomes in children with CTPV by reestablishing physiological portal circulation. Purpose: This study aims to summarize the clinical efficacy and institutional experience in the management of pediatric portal vein cavernous transformation. Methods: A retrospective analysis was conducted on seven children with portal vein cavernous transformation treated at the Department of Pediatric Surgery, First Affiliated Hospital of Xinjiang Medical University, between December 2021 and March 2025. The cohort included four boys and three girls, with ages ranging from 5 years and 10 months to 12 years. All patients had a history of esophagogastric variceal bleeding and hypersplenism. Preoperative evaluations included portal vein color Doppler ultrasonography, abdominal computed tomography angiography (CTA) to assess the portal venous system anatomy and blood flow dynamics. Following a rigorous assessment, six patients underwent living donor liver transplantation, and one patient underwent Rex shunt surgery. Results: All seven surgeries were successfully completed. During a follow-up period ranging from 3 to 42 months, no episodes of gastrointestinal bleeding were observed in any patient. Among the six patients who underwent liver transplantation, no cases of graft rejection, arterial complications, or biliary complications were reported. Postoperatively, all seven patients demonstrated a significant reduction in portal vein pressure and improvement in pancytopenia compared to preoperative values ( Conclusions: While the Rex shunt remains the gold standard for the treatment of portal vein cavernous transformation, living donor liver transplantation provides a viable alternative for patients unsuitable for Rex shunt reconstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.